SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow Health, Inc. - HROW

NEW YORK, March 13, 2023

The investigation concerns whether Harrow and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On February 22, 2023, Bonitas Research ("Bonitas") published a short report addressing Harrow, in which Bonitas stated that "our findings suggest that at best, Harrow is an unprofitable stock promotion neglecting risk disclosures and quality control standards at its compounding pharmaceutical operations." Among other issues, Bonitas cited the Company's receipt of a subpoena from the U.S. Department of Justice in August 2022 "seeking the production of documents related to sales, marketing, and promotional practices related to Dexycu"; the receipt of a U.S. Food and Drug Administration ("FDA") Warning Letter in June 2022 for false and misleading marketing claims; and the receipt of an FDA Form 483 inspection report in August 2022 "which cited unsanitary conditions and drug quality issues." 

On this news, Harrow's stock price fell $0.54 per share, or 3.18%, to close at $16.42 per share on February 22, 2023.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.